Oncology Brothers: Practice-Changing Cancer Discussions
Sep 22, 2026 · 21 min · 8 segments
In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch…
Mazyar ShadmanGuest
Rahul GosainHost
Rohit GosainHost
And just to wrap up here, when we're picking one CAR-T over another here, we said Lysosol based off pilot, transform trial, we saw complete responses like 70%, 75%, whereas historic control was 40%, 45%.
Similar story, Axosol, Zuma 7, active agent, but we have to worry about more side effects.
Maziar, just to close off, when we have different bispecific antibodies, how do you pick one over the other? Epcoritumab, glufitumab, what's your go-to here? And what can we learn from this in community settings?
So it's mainly logistics from, you know, one with BEPCO being a sub-Q with a more complicated schedule of weekly and then every two weeks and every four weeks, and it's treated until progression, not time-limited.
So You know, I think a lot of it depends on what our colleagues in the community have started using, and we usually work with them.
I mean, biospecifics as monotherapy are great, but now we see increasing studies using, combining these biospecifics with either chemo Or ADCs, more interestingly, right? So we have data with Glofid, for example.
We have data in combination with both Polatuzumab, Blanca, and also with Mosonatuzumab, which has monotherapy, is not approved for large cell lymphoma.
The Mosonpola data actually looks very nice and very well tolerated for large cell lymphoma.
EBCO, I think in terms of their combination with ADCs, is a little bit different.
behind but there is data with every chemo and with lenalidomide we'll see if that you know there was a press release and we'll see what the data is there but there's a potential there as well so i think they're good drugs but right now it's mainly defined and directed by the logistics and access and they're both great
And just to wrap up here, when we're picking one CAR-T over another here, we said Lysosol based off pilot, transform trial, we saw complete responses like 70%, 75%, whereas historic control was 40%, 45%.
Similar story, Axosol, Zuma 7, active agent, but we have to worry about more side effects.
Maziar, just to close off, when we have different bispecific antibodies, how do you pick one over the other? Epcoritumab, glufitumab, what's your go-to here? And what can we learn from this in community settings?
So it's mainly logistics from, you know, one with BEPCO being a sub-Q with a more complicated schedule of weekly and then every two weeks and every four weeks, and it's treated until progression, not time-limited.
So You know, I think a lot of it depends on what our colleagues in the community have started using, and we usually work with them.
I mean, biospecifics as monotherapy are great, but now we see increasing studies using, combining these biospecifics with either chemo Or ADCs, more interestingly, right? So we have data with Glofid, for example.
We have data in combination with both Polatuzumab, Blanca, and also with Mosonatuzumab, which has monotherapy, is not approved for large cell lymphoma.
The Mosonpola data actually looks very nice and very well tolerated for large cell lymphoma.
EBCO, I think in terms of their combination with ADCs, is a little bit different.
behind but there is data with every chemo and with lenalidomide we'll see if that you know there was a press release and we'll see what the data is there but there's a potential there as well so i think they're good drugs but right now it's mainly defined and directed by the logistics and access and they're both great
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
